Updated Analysis and Patient-Reported Outcomes (PROs) from CITYSCAPE: A Randomised, Double-Blind, Phase II Study of the anti-TIGIT Antibody Tiragolumab + Atezolizumab (TA) Versus Placebo + Atezolizumab (PA) as First-Line Treatment For PD-L1+ NSCLC

IMreal Cohort 2: first interim analysis of patient (pt) characteristics and safety data in pts with locally advanced or metastatic NSCLC (aNSCLC) receiving atezolizumab (atezo) under real-world conditions

Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Pembrolizumab (Pembro) With or Without Lenvatinib (Lenva) in First-Line Metastatic NSCLC With PD-L1 TPS ≥1% (LEAP-007): A Phase 3, Randomized, Double-Blind Study

RATIONALE 309: A randomized, global, double-blind, Phase 3 trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as 1L treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)

Phase 1 dose escalation of IMC-C103C, a CD3_MAGE-A4 T cell receptor (TCR) bispecific protein

First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors.

IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 Part 1: efficacy by KRAS, STK11, and KEAP1 mutation status

A Phase 1b Study of Lenvatinib + Pembrolizumab (LEN + PEMBRO) in Patients (pts) with Unresectable Hepatocellular Carcinoma (uHCC): Study 116 Follow-up Analysis

Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): a retrospective real-world study (CTONG2004)

Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors

Biomarker analysis from a phase 1b, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors

Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): intracranial and systemic outcomes from Checkmate 227 Part 1

Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC